Navigation Links
Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results

- Completes SAD Portion of the Phase 1 Program for R4996/MEM 63908 -

MONTVALE, N.J., March 6 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY), a biopharmaceutical company focused on the discovery and development of innovative drug candidates for the treatment of a broad range of central nervous system (CNS) conditions, today reported its financial results for the fourth quarter and year ended December 31, 2007.

"We have made significant progress with our clinical and business development efforts in recent months, highlighted by our positive Phase 2a data for MEM 3454 in Alzheimer's disease, the expansion of our schizophrenia development program for MEM 3454 with our partner Roche, and the completion of our single ascending dose Phase 1 study for R4996/MEM 63908," said Vaughn M. Kailian, President & Chief Executive Officer. "During 2008, we look forward to building on this progress as we advance our clinical programs. We expect to complete our ongoing Phase 2a trial for MEM 3454 in cognitive impairment associated with schizophrenia and report top-line data from the study, complete the remaining studies in our Phase 1 program for R4996/MEM 63908, and initiate a biomarker study for MEM 3454 in schizophrenia."

Financial Results

For the quarter ended December 31, 2007, the Company reported a net loss of $9.6 million, or $0.13 per share, compared to a net loss of $14.7 million, or $0.23 per share, for the same period in 2006. For the year ended December 31, 2007, the Company reported a net loss of $35.3 million, or $0.49 per share, compared to a net loss of $31.1 million, or $0.70 per share, in 2006.

For the quarter ended December 31, 2007, the Company reported revenue of $1.1 million, compared to revenue of $2.6 million for the same period in 2006. For the year ended December 31, 2007, the Company reported revenue of $11.5 million, compared to revenue of $9.3 million in 2006. The increase in revenue for the year ended December 31, 2007 is related to recognizing the $2.2 million in milestone payments received from the Stanley Medical Research Institute in connection with the MEM 1003 Phase 2a bipolar disorder clinical trial.

Research and development expenses for the quarter ended December 31, 2007 were $8.3 million compared to $10.5 million for the same period in 2006. The change included a decrease of $3.0 million associated with the clinical development of MEM 1003, offset by an increase of $0.5 million in manufacturing costs. Research and development expenses for the year ended December 31, 2007 were $38.4 million compared to $33.8 million for the same period in 2006. The change included an increase of $4.2 million associated primarily with the clinical development of MEM 3454 and an increase of $0.7 million in personnel and personnel-related costs.

General and administrative expenses for the quarter ended December 31, 2007 were $2.2 million, compared to $1.8 million for the same period in 2006. The change included an increase of $0.4 million in personnel and personnel- related costs. General and administrative expenses for the year ended December 31, 2007 were $9.3 million compared to $8.4 million for the same period in 2006. The change included an increase of $0.8 million in personnel and personnel-related costs.

At December 31, 2007, the Company had cash, cash equivalents and marketable securities of approximately $38.2 million, compared to $51.3 million at the end of 2006. The Company now expects that its existing cash, cash equivalents, and marketable securities, together with payments expected to be made under its collaboration agreements, should be sufficient to fund operating expenses, debt obligations and capital equipment requirements into the first half of 2009.

Fourth Quarter Highlights and Recent Developments

-- Nicotinic Alpha-7 Receptor Agonist Program

MEM 3454. In November 2007, Memory Pharmaceuticals reported positive

top-line results from its Phase 2a trial of MEM 3454, a nicotinic

alpha-7 receptor agonist, in Alzheimer's disease, demonstrating a

statistically significant effect on multiple measures of cognition.

In December 2007, the Company commenced a Phase 2a trial of MEM 3454

in cognitive impairment associated with schizophrenia (CIAS). The

trial is expected to enroll approximately 160 patients and is designed

to assess the safety, tolerability and cognitive effects of three

doses of MEM 3454 in patients with CIAS. The Company plans to

announce top-line results from this trial in the fourth quarter of


In February 2008, Memory Pharmaceuticals announced that it plans to

conduct a clinical study of MEM 3454 on two biomarkers of

schizophrenia, P50 sensory gating and mismatch negativity, in patients

with schizophrenia. The biomarker study, and additional formulation

and manufacturing activities for MEM 3454, will be funded by Roche.

The Company expects to begin the study this summer, with data

available by early 2009.

R4996/MEM 63908. Memory Pharmaceuticals reported today that it has

completed the single ascending dose (SAD) portion of its Phase 1 study

for R4996/MEM 63908, a partial agonist of the nicotinic alpha-7

receptor. The randomized, double-blind, placebo-controlled study

evaluated the safety, tolerability and pharmacokinetics of ascending

doses of R4996/MEM 63908 in healthy adult male volunteers. As part of

the Phase 1 clinical program for R4996/MEM 63908, the Company is now

conducting a food interaction study in healthy adult male volunteers

and a randomized, placebo-controlled single dose study in elderly male

and female volunteers, and plans to commence a multiple ascending dose

study. The Company now expects to announce the top-line data from the

Phase 1 program in the fourth quarter of 2008.

-- MEM 1003. In October 2007, Memory Pharmaceuticals announced top-line

data from its Phase 2a study of MEM 1003 in Alzheimer's disease. The

trial failed to meet its primary endpoint, which was a twelve-week

mean change in the Alzheimer's disease Assessment Scale -- Cognitive

subscale (ADAS-cog) score in the overall population, due primarily to

an unusually large placebo response in the subgroup of monotherapy

subjects. In the subgroup of subjects receiving cholinesterase

inhibitors, the change in ADAS-cog favored treatment over placebo and

numeric improvements were seen in all of the four secondary endpoints.

The Company plans to complete its analysis of the data from this trial

and evaluate the potential for further development of this drug


-- Leadership Team

Interim President and Chief Executive Officer. In February 2008,

Memory Pharmaceuticals appointed Vaughn M. Kailian interim President

and Chief Executive Officer. Jim Sulat, the Company's President and

Chief Executive Officer since 2005, stepped down for personal family

reasons and will serve as the Company's Chief Financial Officer on a

part-time basis. In support of Mr. Kailian's appointment, four of the

Company's largest shareholders, MPM Capital, Great Point Partners,

Oxford Biosciences and Venrock, agreed to a six-month lock-up

agreement. The Board has commenced a search for a full-time Chief

Executive Officer.

New Board Member. In November 2007, Paul Blake, M.B., currently

Senior Vice President and Chief Medical Officer of AEterna Zentaris

Inc., joined Memory Pharmaceuticals' Board of Directors. Dr. Blake

has over 27 years of clinical development experience, including

previous positions at Avigenics Inc., Cephalon, Inc., MDS Proteomics,

Inc. and SmithKline Beecham Pharmaceuticals.

Conference Call and Webcast Information

Memory Pharmaceuticals will hold a conference call on March 6, 2008, at 9:00 a.m. EST to discuss the Company's fourth quarter and full year 2007 financial results. The conference call will also be broadcast live from the "Investors" section of the Company's website. Memory Pharmaceuticals' senior management will host the conference call. Investors and other interested parties may access the call as follows:

Date: Thursday, March 6, 2008

Time: 9:00 a.m. EST

Telephone (U.S.): 800.599.9829

Telephone (international): 617.847.8703

Participant Passcode: 91069592


under the "Investors" section

An audio replay of the conference call will be available from 11:00 a.m. EST on Thursday, March 6, 2008, until Thursday, March 13, 2008. To access the replay, please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enter passcode number 63677090. An audio replay of the conference call will also be available under the "Investors" section of the Company's website during the same period.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties associated with: obtaining additional financing to support Memory Pharmaceuticals' R&D and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationships; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; protecting the intellectual property developed by or licensed to Memory Pharmaceuticals; and Memory Pharmaceuticals ability to maintain listing on the Nasdaq Global Market. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.



(in thousands - except share and per share information)


Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

---------- ---------- ---------- ----------

Revenue $ 1,075 $ 2,640 $ 11,519 $ 9,322

Operating expenses:

Research and

development 8,258 10,534 38,354 33,800

General and

administrative 2,220 1,767 9,324 8,444

---------- ---------- ---------- ----------

Total operating

expenses 10,478 12,301 47,678 42,244

---------- ---------- ---------- ----------

Loss from operations (9,403) (9,661) (36,159) (32,922)

---------- ---------- ---------- ----------

Other income (loss) 64 (6,048) 64 (247)

Interest income

(expense), net (217) 586 813 1,674

---------- ---------- ---------- ----------

Loss before income taxes (9,556) (15,323) (35,282) (31,695)

Income tax (benefit)

expense - (396) 3 (388)

---------- ---------- ---------- ----------

Net loss $ (9,556) $ (14,727) $ (35,285) $ (31,107)

========== ========== ========== ==========

Basic and diluted net

loss per share of

common stock $ (0.13) $ (0.23) $ (0.49) $ (0.70)

========== ========== ========== ==========

Basic and diluted

weighted average

number of shares of

common stock

outstanding 72,645,081 63,831,072 71,874,757 44,334,129



(in thousands)


December 31, 2007 December 31, 2006

----------------- -----------------


Cash, cash equivalents and

marketable securities $ 38,201 $ 51,323

Other current assets 1,417 1,397

Restricted cash 505 509

Deferred financing costs, net 519 -

Property and equipment, net 5,868 7,413

----------------- -----------------

Total assets $ 46,510 $ 60,642

================= =================


Current liabilities

(excluding deferred revenue) $ 8,789 $ 7,664

Warrant liability - 8,724

Equipment notes payable, less current

portion 66 345

Loan payable, less current portion 10,831 -

Deferred revenue 18,051 20,707

Other non-current liabilities 506 -

----------------- -----------------

Total liabilities 38,243 37,440

Stockholders' equity 8,267 23,202

----------------- -----------------

Total liabilities and stockholders'

equity $ 46,510 $ 60,642

================= =================

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
2. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
3. Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease
4. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
5. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
6. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
7. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
8. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
9. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
10. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
11. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Post Your Comments:
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/7/2017)... 2017   Provista, a proven leader in ... in purchasing power, today announced a new resource area ... Newsroom is the online home for case studies, ... bios, news releases, slideshows and events. ... of resources at their fingertips, viewers can also watch ...
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... of $3,296 in property taxes a year. In some states—like New York, New ... , By contrast, many overseas retirement havens have extremely low property-tax rates, which ...
Breaking Medicine News(10 mins):